Who we are
AusCann is an Australian-based company focused on the development and commercialisation of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally.
Our key difference is the commitment to rigorous product development, focused on providing reliable, stable and standardised cannabinoid-derived therapeutics products, whilst generating robust safety, quality assurance and efficacy data to support market access in various regulatory environments around the world.
What we do
Improve health outcomes and quality of life for patients and pets around the world.
We have built a strong team of experts and partners in both human and animal health, with the right expertise across all aspects of both the pharmaceutical and nutraceutical value chains.
Our immediate focus is on providing both healthcare professionals and veterinarians with solutions to optimise treatment outcomes for patients and for pets. To do that, we have developed innovative technologies to enhance the delivery of our novel formulations and aim to commercialise our products through various regulatory frameworks around the world.
How we improve human health
Driven by unmet medical needs and backed by pharmaceutical and nutraceutical science, AusCann aims to transform the way cannabinoid and hemp-derived products are used today by developing and making available a range of standardised, innovative and reliable products with a focus on safety and quality assurance.
The Company has launched novel tetrahydrocannabinol and cannabidiol (THC/CBD) powder-based hard-shell capsules, based on AusCann’s proprietary Neuvis® platform, for the treatment of pain and related indications. The capsules address key concerns raised by healthcare professionals for alternative cannabinoid dose forms, which offer enhanced patient compliance, ease-of-use for patients with dexterity issues, dose uniformity and eliminate potential in-use contamination.
Further Information for healthcare professionals regarding our standardised THC/CBD powder-based capsules using the Neuvis® drug delivery system is available at neuvis.com
How we improve animal health
CannPal Animal Therapeutics, a subsidiary of AusCann Group Holdings, is a global leader in the development of innovative, cannabinoid-derived therapeutic products to provide veterinarians and pet owners with clinically validated and standardised therapeutics to treat animals in a safe and more natural way.
Presently, the Company is developing products based on CBD, THC and other active ingredients for registration as veterinary medicines and nutraceuticals in the areas of pain, inflammation, mood and dermatological skin conditions.
Further information is available at www.cannpal.com